RHJA
OBIO icon

Rice Hall James & Associates’s Orchestra BioMed OBIO Stock Holding History

Rice Hall James & Associates’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.83M Buy
424,000
+404,999
+2,131% +$1.66M 0.09% 182
2026
Q1 		$80.8K Buy
+19,001
New +$80.9K ﹤0.01% 243

Other funds holding OBIO

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Rice Hall James & Associates's OBIO Position: Q2 2026 in Review

Rice Hall James & Associates increased its Orchestra BioMed (OBIO) stake by 2,131% in Q2 2026, buying an estimated $1.66M and bringing the position to 424,000 shares worth $1.83M. The position accounts for 0.09% of the portfolio, ranked #182.

Rice Hall James & Associates first reported a position in OBIO in Q1 2026 and has held it in 2 quarters since. 77 funds tracked by Wall St. Rank hold OBIO as of Q2 2026.

  • Rice Hall James & Associates held 424,000 shares of Orchestra BioMed worth $1.83M as of Q2 2026.
  • Rice Hall James & Associates bought 404,999 Orchestra BioMed shares in Q2 2026, an estimated $1.66M.
  • Orchestra BioMed made up 0.09% of Rice Hall James & Associates's portfolio in Q2 2026, its #182 holding.
  • Rice Hall James & Associates first reported a position in Orchestra BioMed in Q1 2026 and has held it in 2 quarters since.
  • 77 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2026.

Based on Rice Hall James & Associates's 13F filing for Q2 2026, filed 7 Aug 2026.